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STUDY PROTOCOL Open Access
Enhancing Cancer care of rural dwellers
through telehealth and engagement
(ENCORE): protocol to evaluate
effectiveness of a multi-level telehealth-
based intervention to improve rural cancer
care delivery
Tuya Pal1,2, Pamela C. Hull3,4, Tatsuki Koyama1,5, Phillip Lammers6, Denise Martinez7, Jacob McArthy7,
Emma Schremp7, Ann Tezak2, Anne Washburn1, Jennifer G. Whisenant8 and Debra L. Friedman1,7*
Abstract
Background: Despite lower cancer incidence rates, cancer mortality is higher among rural compared to urban
dwellers. Patient, provider, and institutional level factors contribute to these disparities. The overarching objective of
this study is to leverage the multidisciplinary, multispecialty oncology team from an academic cancer center in
order to provide comprehensive cancer care at both the patient and provider levels in rural healthcare centers. Our
specific aims are to: 1) evaluate the clinical effectiveness of a multi-level telehealth-based intervention consisting of
provider access to molecular tumor board expertise along with patient access to a supportive care intervention to
improve cancer care delivery; and 2) identify the facilitators and barriers to future larger scale dissemination and
implementation of the multi-level intervention.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
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licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
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Methods: Coordinated by a National Cancer Institute-designated comprehensive cancer center, this study will
include providers and patients across several clinics in two large healthcare systems serving rural communities.
Using a telehealth-based molecular tumor board, sequencing results are reviewed, predictive and prognostic
markers are discussed, and treatment plans are formulated between expert oncologists and rural providers.
Simultaneously, the rural patients will be randomized to receive an evidence-based 6-week self-management
supportive care program, Cancer Thriving and Surviving, versus an education attention control. Primary outcomes
will be provider uptake of the molecular tumor board recommendation and patient treatment adherence. A mixed
methods approach guided by the Consolidated Framework for Implementation Research that combines qualitative
key informant interviews and quantitative surveys will be collected from both the patient and provider in order to
identify facilitators and barriers to implementing the multi-level intervention.
Discussion: The proposed study will leverage information technology-enabled, team-based care delivery models in
order to deliver comprehensive, coordinated, and high-quality cancer care to rural and/or underserved populations.
Simultaneous attention to institutional, provider, and patient level barriers to quality care will afford the opportunity
for us to broadly share oncology expertise and develop dissemination and implementation strategies that will
enhance the cancer care delivered to patients residing within underserved rural communities.
Trial registration: Clinicaltrials.gov, NCT04758338. Registered 17 February 2021 – Retrospectively registered, http://
www.clinicaltrials.gov/




Several studies have documented elevated cancer inci-
dence and/or mortality in rural compared to urban com-
munities [1–7], particularly pronounced in certain
regions of the United States (US), including the South
[8]. These differences have broad population health im-
plications as almost 20% of Americans live in rural areas
[8, 9], but only 10% of physicians practice there [10].
Rural counties have some of the highest rates of poverty,
where residents are faced with limited availability to can-
cer treatment and supportive care services, transporta-
tion barriers, and financial issues [11–15]. Similarly,
challenges are faced by rural providers in delivering can-
cer care to their patients, with limited access to compre-
hensive care being the most important reason for
outcome disparities [16]. Moreover, the growing divide
in mortality between rural and urban dwellers [1, 5, 17–
19] highlights the need to evaluate multi-level interven-
tions directed at providers and their patients to improve
outcomes.
Suggested strategies to enhance rural cancer care to al-
leviate issues associated with long travel distances com-
prise technology-based approaches to deliver remote
care delivery, inclusive of education and supportive care
[12]. Telehealth use in rural communities allows exten-
sion of care to wide geographic regions without patient
or provider travel. An Institute of Medicine report noted
that telehealth for rural hospitals drives volume and in-
creases quality of care, while preserving low cost [20].
Telehealth has been successfully used for cancer screen-
ing, treatment, and supportive care [21–26], and been
expanded even further especially in the post COVID-19
era [27–31].
Provision of optimal cancer care delivery also requires
multispecialty and multidisciplinary input. Tumor
boards contribute to such input and provide evidence-
and consensus-based data to optimize cancer treatment
and can be accessed virtually with interactive participa-
tion from large geographical regions [32–34]. With the
advent of next generation sequencing (NGS), the use of
tumor boards has expanded to meet new challenges
faced for physicians and patients, with respect to inter-
pretation of results and translation to clinical interven-
tions. To meet this need, we and others have developed
successful telehealth-based molecular tumor boards,
which enable community oncologists to present cases in
real time to an academic cancer center [35–37]. This is
particularly salient in rural communities, where there
are fewer oncologists and, subsequently, are faced with
the challenge of being well versed in the rapidly-
changing molecular architecture of multiple tumor
types. Additionally, late stage disease at initial diagnosis
may be more common in rural patients [4] where mo-
lecular tumor diagnostics are more likely to direct tar-
geted treatments. Therefore, telehealth-based molecular
tumor boards offer a mechanism to disseminate
evidence-based information from a National Cancer In-
stitute (NCI)-comprehensive cancer center to its rural
catchment area.
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Supportive care self-management interventions
Self-management support is the systematic provision of
education and supportive care to increase the patients’
skills and confidence in managing their health problems
and is an integral component of the Chronic Care Model
[38–42]. Self-management interventions for cancer have
been developed with face-to-face, online and telehealth
models to minimize treatment-related symptoms and
distress, improve treatment adherence and psychosocial
wellbeing, and promote survival [39, 43–48]. The
Chronic Disease Self-Management Program (CDSMP) is
an evidence-based self-management intervention with
demonstrated efficacy across numerous chronic health
conditions with dissemination across the US, inclusive of
rural communities, and to 25 countries [40, 49–53]. The
CDSMP adaptation for cancer patients, Cancer Thriving
and Surviving (CTS), has demonstrated efficacy in im-
proving patient-provider communication, energy, and
sleep, and reducing depression and stress-related
problems [48, 54]. Yet access to such programs is limited
in rural communities with wide geographic areas. There-
fore, evaluation of the effectiveness of the evidence-
based CTS intervention delivered through telehealth
among rural patients is needed given its potential to im-
prove patient outcomes.
Objectives and aims
The goal of this project is to assess improvement in de-
livery of quality cancer care using a multi-level telehealth
technology intervention tested at both the provider level
and the patient level in the rural catchment area of
Vanderbilt-Ingram Cancer Center (VICC), an NCI-
designated Comprehensive Cancer Center (Fig. 1). To
achieve this goal, this study has two specific aims:
Aim 1
Evaluate the clinical effectiveness of a multi-level
telehealth-based intervention for rural hospitals
Fig. 1 Location of Participating Vanderbilt Health Affiliate Network sites serving rural counties within the VICC Catchment area. This figure
illustrates the study’s catchment area throughout Tennessee and Mississippi, including a distinction between rural versus non-rural counties. Each
number represents the location of one of nine participating hospitals through the Vanderbilt Health Affiliated Network (VHAN), including seven
through the Baptist Memorial Health Care Corporation and two through Ballad Health. This figure was created by the authors specifically for this
clinical trial protocol
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consisting of provider access to tumor board expertise
that incorporates disease, patient, and molecular tumor
characteristics, together with patient access to a support-
ive care intervention to improve cancer care delivery.
Aim 2
Identify the facilitators and barriers to future larger scale
dissemination and implementation of the multi-level
intervention, designed to enhance the quality of rural
cancer care delivery.
Conceptual framework for implementation
In order to identify potential barriers and facilitators that
may influence implementation and future dissemination
and to understand “what ‘works where and why’ across
multiple contexts” during and after implementation [55,
56], an implementation framework is helpful. The Con-
solidated Framework for Implementation Research
(CFIR), a meta-theoretical framework that delineates a
taxonomy of concepts to examine the process of imple-
mentation [55], was chosen for the current study as out-
lined in Fig. 2. The CFIR Outer Setting domain includes
factors outside of the implementing organizations such
as: patient needs and resources, the degree to which the
hospitals are networked with external organizations
(cosmopolitanism), peer competition with other hospi-
tals, and external policies and incentives, such as
evidence-based expert practice guidelines and criteria for
treatment and reimbursement. The Inner Setting do-
main reflects characteristics of the organizations
implementing the intervention (VICC and rural hospi-
tals): structural characteristics (organization size, age,
maturity), the nature and quality of organization’s in-
ternal communications, general organizational culture,
implementation climate (intention for change, compati-
bility, relative priority, organizational incentives, goals/
feedback, learning climate), and the organization’s inter-
ventional readiness (leadership engagement, available re-
sources for sustainability, access to information).
Methods/design
Overall study design
This study will utilize information technology (IT)-en-
abled, team-based care delivery models to provide com-
prehensive, coordinated, high-quality cancer-related care
focused on rural populations. The study schema is pre-
sented in Fig. 3. We will evaluate the clinical effective-
ness of a multi-level telehealth-based intervention in
hospitals that see large volumes of rural patients. The
intervention consists of provider access to tumor board
expertise that incorporates disease, patient, and molecu-
lar tumor characteristics along with patient access to a
supportive care intervention to improve cancer care de-
livery (Aim 1), and identification of facilitators and bar-
riers to enable future larger scale dissemination and
implementation of the multi-level intervention that is
designed to enhance the quality of rural cancer care de-
livery (Aim 2). Simultaneous attention to institutional,
provider, and patient level barriers to quality care will
provide the opportunity for VICC, located in a region of
Fig. 2 Conceptual Framework: Implementation of Evidence-Based Cancer Care Delivery to Rural Populations via Telehealth. This figure illustrates
the conceptual framework for implementation of the multi-level telehealth intervention to bring evidence-based comprehensive cancer care to
patients in rural counties in Tennessee. The white blocks on the left indicate that we will evaluate the clinical effectiveness of delivering a multi-
level telehealth intervention to rural hospitals to improve cancer care delivery, consisting of 1) provider-level access to tumor board expertise that
incorporates disease, patient, and molecular tumor characteristics, and 2) patient-level access to a supportive care intervention (Aim 1). The dark
gray block on the top right outlines the intervention outcomes. The gray blocks in the middle illustrate domains and subdomains of the CFIR
that we will examine during intervention delivery to identify barriers and facilitators to future larger scale dissemination and implementation of
the intervention (Aim 2)
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the country with some of the highest cancer mortality
rates [57], to broadly share oncology expertise, as well as
develop dissemination and implementation strategies to
remotely enhance patient care to underserved rural
communities.
Study setting
VICC is the sole NCI-designated Comprehensive Cancer
Center in Tennessee serving adult as well as pediatric can-
cer patients. The geographic placement of VICC, as well
as the regionally-renowned expertise in cancer care, pre-
sents a tremendous opportunity to develop strategies to
address regional disparities in rural cancer care, including
remote access to oncology expertise and supportive care.
Participating healthcare sites will include multiple
oncology practices (i.e., cancer clinics) within the
Vanderbilt Health Affiliated Network (VHAN), includ-
ing the Baptist Memorial Health Care Corporation
and Ballad Health. Participants will include oncology
providers and patients at the aforementioned partici-
pating healthcare sites. The eligibility criteria are: 1)
At least 21 years of age or older and English speaking
with the ability to provide informed consent; 2) On-
cology providers must treat patients within the desig-
nated VHAN oncology practices; 3) Patients with
newly diagnosed or relapsed disease that are patients
of the aforementioned oncology providers; and 4) Ac-
cess to a reliable, video-capable device with internet
access.
Fig. 3 Study schema. VICC, Vanderbilt-Ingram Cancer Center; HOPE, Hereditary and Oncologic Personalized Evaluation; CTS, Cancer Thriving and
Surviving intervention; EMR, electronic medical record
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Data collection
This study will implement provider-level and patient-
level interventions using a mixed-methods approach.
The CFIR will be used to examine intervention delivery
to identify barriers and facilitators to future dissemin-
ation and implementation of the intervention [55, 56].
Both quantitative and qualitative data collection mea-
sures will be used, including baseline surveys before
intervention implementation surveys, qualitative inter-
views, and follow-up surveys after intervention. Provider
and patient recruitment along with the various surveys
that will be conducted per study phase (i.e., Enrollment
Phase, Tumor Board Phase, and Post-Intervention
Phase) are presented in Fig. 4.
Provider-level intervention and data collection
The provider will be asked to complete a baseline survey to
collect demographic information, including gender, age, race,
ethnicity, and number of years post fellowship training. In
addition to demographics, this survey will also assess the fi-
nancial, emotional, and educational needs of rural cancer pa-
tients, and interest in expansion of telehealth services. To
measure relative advantage (CFIR intervention characteris-
tic), providers will be asked to rate on a scale of 1–10 the
perceived need for remote access to the molecular tumor
board, perceived importance of educational and self-
management interventions for their patients, and interest in
participating in future research. An open-ended qualitative
item will ask for suggestions of needed support for the
intervention.
At the tumor board, genomic, histologic, and clinical
data will be presented for further discussion and recom-
mendations. The oncologist, with their patient, will de-
cide if they will proceed with the recommendations, or
alternatively, start another treatment. Recommendations
and treatment changes will be collected.
Key informant interviews will be conducted with up to
10 participating oncologists at two points in time: 1)
early implementation phase (six months after interven-
tion initiation); and 2) maintenance phase (two years
after initiation). The interview questions are adapted
from the existing CFIR Interview Guide [58], covering
the selected constructs under each of the five CFIR
major domain. Interviews will be conducted by tele-
phone using a semi-structured interview guide and will
last about 20 min; all interviews will be audio recorded.
Patient-level intervention and data collection
If the patient expresses interest in the study, the pro-
vider will confirm eligibility then prompt them to
complete the informed consent. If reliable access to a
device with video and internet access is not available, a
device will be mailed to patient’s home after they enroll
and a data plan will be provided. These two resources
will come at no cost to the patient, and the device will
be returned at the conclusion of the study. Reasons for
lack of participation will be tracked as a potential barrier
to future dissemination.
Consented participants will be asked to complete a
baseline survey to collect demographic information,
Fig. 4 Recruitment and surveys conducted at the provider level and patient level per study phase. The action and particular survey that will be
completed by both the provider and patient for the Enrollment Phase, Tumor Board Phase, and Post-Intervention Phase is illustrated. MTB,
molecular tumor board; CTS, Cancer Thriving and Surviving
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including race, ethnicity, highest level of education, an-
nual household income, and zip code; age and gender
will be extracted from the medical record. Participants
will then be randomized (1:1) into the CTS Program
Arm or Education Attention Control Arm (Fig. 3). Par-
ticipants randomized to CTS will have a 6-week inter-
vention delivered via telehealth using the VUMC
telehealth services (Table 1).
Key informant interviews will be conducted with up to
25–30 patient participants in the CTS arm of the study
approximately 6 months after the last session of the inter-
vention. An index combining all of the patient-level out-
come variables at pre-intervention and post-intervention
will be created to calculate the pre-post difference with
positive values indicating an improvement and negative
values indicating a decrease. The interview questions are
adapted from the existing CFIR Interview Guide [58], cov-
ering the selected constructs under each of the five CFIR
major domain. Interviews will be conducted by telephone
using a semi-structured interview guide and lasting about
20min; all interviews will be audio recorded.
Participants in the Education Attention Control Arm
will receive publicly available online educational mate-
rials compiled in a password protected website that
broadly covers the same topics as the CTS syllabus and
enables the study team to track how the participant nav-
igates through these educational materials. All materials
are drawn from preexisting public domains such as the
National Institutes of Health, NCI, and the American
Society of Clinical Oncology.
Data analysis
Data will be analyzed sequentially in three phases:
quantitative-qualitative-quantitative (i.e., baseline survey,
interviews, and follow-up surveys). We will use connect-
ing processes to combine both types of data, thus allow-
ing one dataset to build upon another dataset in each
sequential phase.
Process evaluation data
Implementation penetration will be assessed as a ratio of
number of patients who participate in each group di-
vided by total number of potential participants at each
recruitment site. The recruitment rate will be calculated
as the number of weeks required to recruit at least eight
participants in each arm of the patient-level component.
To address execution, three dimensions of intervention
fidelity for the CTS program will be measured. Adher-
ence of the group facilitators to the CTS protocol will be
measured using an adapted Fidelity Checklist [59] com-
pleted by the facilitators to document completion of re-
quired activities. Exposure of patients to the intervention
will be measured using participation/attendance logs and
website analytics on usage of the online information.
Participant responsiveness will be measured as satisfac-
tion with the intervention from the post surveys. These
measures will be combined into a fidelity score. Other
data collected will include patient cancer type and stage,
institution size, practice size, and number of rural coun-
ties with persistent poverty served and deprivation index,
as indicators of structural characteristics.
Qualitative data
Audio recordings will be transcribed with no identifiers.
Qualitative software (e.g., ATLAS.ti or RQDA) will be
used to code the transcripts using the CFIR Codebook
Template [58]. A thematic analysis method to identify
and analyze commonly recurring themes will be used
Table 1 Cancer Surviving and Thriving Syllabus
Week 1:
• Introduction to the Workshop
• Group Introductions
• The Mind/Body Connection/Distraction
• Fatigue Management and Getting Help
• Introduction to Action Plans
Week 4:
• Feedback




• Making an Action Plan
Week 2:
• Feedback/Problem Solving
• Dealing with Difficult Emotions
• Getting a Good Night’s Sleep
• Regaining Fitness During and after Cancer Treatment




• Making Decisions about Treatment and Complementary Therapies
• Maintaining a Healthy Weight
• Dealing with Depression
• Positive Thinking




• Living with Uncertainty
• Making Decisions
• Future Plans for Healthcare
• Making an Action Plan
Week 6:
• Feedback/Problem-Solving
• Cancer and Relationships
• Guided Imagery
• Working with Your Healthcare Professional
• Looking Back and Planning for the Future
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[60], then themes will be summarized for each group.
Open-ended qualitative responses from surveys will be
coded into categories based on emergent themes, then
merged with the quantitative data sets as categorical
variables.
Quantitative data and intervention outcomes
Survey data will primarily be summarized with descrip-
tive statistics (i.e., frequencies/percentages for categorical
variables and means/standard deviations for continuous
variables) along with bivariate comparisons across sites
and between provider and patient data, where appropri-
ate using chi-squared tests, t-tests, and analysis of
variance.
The primary outcomes will be provider uptake of the
VICC HOPE molecular tumor board treatment recom-
mendation and patient treatment adherence. Secondary
outcomes include progression-free survival (PFS), patient
functional and psychosocial well-being, and patient-
provider communication. Outcomes will be compared
between the CTS and attention control groups. Table 2
provides a list of the tools that will be utilized to meas-
ure these outcomes.
For the provider primary outcome, a logistic regression
model will be fit with the following patient-level,
provider-level, and institution-level variables as potential
effect modifiers. Patient-level includes: cancer type, race,
ethnicity, age and gender; provider-level includes: age,
years since completion of fellowship training, race, eth-
nicity, gender; and institution-level includes: institution
size (number of inpatient beds and outpatient infusion
chairs), practice size (oncologists, nurses, advanced prac-
tice providers) and number of rural counties with per-
sistent poverty served. Note that the outcome will most
likely be correlated within the same provider, and to ac-
count for this correlation, we will use generalized esti-
mating equations (GEE) with an independent weight
matrix. Because the CTS Program Arm will be delivered
to a group of 8 to 10 patients at a time, we will consider
this as a crossed random effect. The Education Attention
Control Arm will not have groups, and we will treat
each individual as their own group to fit the model.
Institution-level data will be used as fixed effects.
The secondary endpoints will be analyzed similarly
using the regression approach taking into account the
potential clustering effect of the treatment delivery
group and practice. For a continuous outcome, mixed-
effects model will be used; for PFS, we will use mixed ef-
fects Cox regression model to account for the interven-
tion group clusters.
Sample size and power analysis
We expect to present 450 cases to the molecular tumor
board, and we expect 300 patients to be randomized at 1
to 1 to the two treatment groups. For the patient-level
intervention, we can detect treatment effect (difference
in binary outcome) if the true successful (adherence)
proportions are 75% (telehealth) and 60% (control) with
80% power while controlling type I error rate at 5%.
Discussion
Participation in this study will directly test the clinical
effectiveness of a telehealth implementation strategy for
disseminating genomic cancer information for optimal
patient care across diverse communities within and be-
yond the catchment area of VICC. This will allow itera-
tive development of best practices for cancer care
delivery to rural communities. This study is testing a
novel multi-level intervention with simultaneous evalu-
ation of provider and patient components to improve
cancer care among underserved individuals in rural
communities. A multi-level intervention to assess im-
provement in delivery of quality cancer care will be
tested: 1) at the provider level through access to an
existing telehealth-based molecular tumor board and
availability to disease-specific expertise at VICC; and 2)
the patient level through a telehealth-based supportive
care intervention.
Using the CFIR model, we chose a multi-level inter-
vention that includes both provider and patient level
components. However, as such, it may be difficult to de-
termine the relative contribution of each of the
Table 2 Assessment surveys that will be used to evaluate outcomes from the provider and patient
Name of Tool Measurement
The Visual Analogue Scale [61] Patients mark a line at the point along a continuum showing how much of each drug they have taken in the
past month
The Distress Thermometer [62] Level of patient distress (0–10 scale) and problems contributing to it
The Functional Assessment of Cancer
Therapy [63]
Health related quality of life in four primary domains: physical well-being, social/family well-being, emotional
well-being, and functional well-being
The MD Anderson Symptom
Inventory [64]
Thirteen common symptoms faced by cancer patients for severity and interference with aspects of daily life
on a 10-point numeric rating scale
The Communication Assessment Tool
[65]
Patients rate communication with the physician on a 15-item instrument that employs a five-point response
scale
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components. To overcome this limitation, we have de-
veloped some analyses of each component for Aim 1
and will look across institutional, provider, and patient
levels for barriers and facilitators for future larger scale
implementation in Aim 2. In addition, there may be
cases with only an oncologist or patient participant.
While we don’t expect this to be a high number, dis-
cordant participation will reflect real world circum-
stances and inform future dissemination and
implementation strategies.
As with all telehealth services, this study could be chal-
lenged by technical difficulties. However, VICC has suc-
cessfully brought telehealth into rural counties with low
broadband connectivity. This includes combined use of
computers, tablets and smart phones for the participants.
To date, we have had no issues with VICC telehealth across
a number of service lines and research projects. Addition-
ally, through the Vanderbilt University Medical Center
(VUMC), an institutional infrastructure exists for health-
care providers to deliver telehealth-based services. This
existing VUMC telehealth infrastructure and software is
available for use in the proposed study and access to broad-
band and devices will be provided to participants if needed.
This will inform future scaling of this intervention.
Summary and impact
With the proposed multi-level remote intervention, we
will 1) improve comprehensive cancer care delivery to
patients residing in rural communities with persistent
poverty; 2) use telehealth to broaden the reach of our
NCI-designated comprehensive cancer center in these
communities; 3) disseminate evidence-based information
to rural oncology providers using a tumor board to share
expertise in molecular tumor analysis and interpretation;
4) provide guidance on cutting-edge therapies based on
patient, disease, and tumor characteristics; and 5) offer
an evidence-based self-management intervention to rural
patients. Furthermore, we will collect data for future dis-
semination and implementation of this intervention in
order to decrease disparities in rural cancer patients with
limited access to comprehensive care.
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